{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T23:14:27Z","timestamp":1696547667745},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.beha.2011.03.001","type":"journal-article","created":{"date-parts":[[2011,5,12]],"date-time":"2011-05-12T05:53:19Z","timestamp":1305179599000},"page":"257-270","source":"Crossref","is-referenced-by-count":10,"title":["Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL"],"prefix":"10.1016","volume":"24","author":[{"given":"Emmanuel","family":"Bachy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5 Suppl. 5","key":"10.1016\/j.beha.2011.03.001_bib1","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"issue":"33","key":"10.1016\/j.beha.2011.03.001_bib2","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2011.03.001_bib3","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1200\/JCO.2005.03.911","article-title":"Improved survival for patients with follicular lymphoma","volume":"23","author":"Lister","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.001_bib4","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2011.03.001_bib5","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2011.03.001_bib6","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2011.03.001_bib7","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2011.03.001_bib8","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2004.07.170","article-title":"Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma","volume":"22","author":"Zinzani","year":"2004","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.beha.2011.03.001_bib9","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2011.03.001_bib10","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2001.19.3.727","article-title":"High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin\u2019s lymphoma: a case-matched study from the European Bone Marrow Transplant Registry","volume":"19","author":"Williams","year":"2001","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2011.03.001_bib11","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1023\/A:1008399623564","article-title":"High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol","volume":"11","author":"Brice","year":"2000","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.beha.2011.03.001_bib12","first-page":"157","article-title":"Value of autologous bone marrow transplantation in follicular lymphoma: a France autogreffe retrospective study of 42 patients","volume":"13","author":"Colombat","year":"1994","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"10.1016\/j.beha.2011.03.001_bib13","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJM199111283252201","article-title":"Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma","volume":"325","author":"Gribben","year":"1991","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2011.03.001_bib14","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.1994.12.6.1177","article-title":"Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma","volume":"12","author":"Rohatiner","year":"1994","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2011.03.001_bib15","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/blood.V86.8.3257.3257","article-title":"Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma","volume":"86","author":"Bastion","year":"1995","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2011.03.001_bib16","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2011.03.001_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2000.18.3.527","article-title":"High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up","volume":"18","author":"Apostolidis","year":"2000","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.beha.2011.03.001_bib18","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.001_bib19","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2011.03.001_bib20","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2011.03.001_bib21","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2011.03.001_bib22","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","article-title":"Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA)","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2011.03.001_bib23","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.V89.3.801","article-title":"High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin\u2019s disease: analysis of the Stanford University results and prognostic indices","volume":"89","author":"Horning","year":"1997","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2011.03.001_bib24","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2004.10.054","article-title":"Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2011.03.001_bib25","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1182\/blood.V77.11.2524.2524","article-title":"Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin\u2019s lymphoma","volume":"77","author":"Freedman","year":"1991","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2011.03.001_bib26","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","article-title":"Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study","volume":"26","author":"Sebban","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.001_bib27","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.773.773","article-title":"Autologous stem sell transplantation (auto-SCT) as the treatment of choice for follicular lymphoma patients in first relapse: final analysis of the outcome of 175 patients treated in the GELA\/GOELAMS FL 2000 Study","volume":"112","author":"Le Gouill","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2011.03.001_bib28","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/bmt.2009.294","article-title":"Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up","volume":"45","author":"Magni","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.beha.2011.03.001_bib29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/annonc\/mdh090","article-title":"Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin\u2019s lymphoma: a single institution study","volume":"15","author":"Belhadj","year":"2004","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.beha.2011.03.001_bib30","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/annonc\/mdn044","article-title":"Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma","volume":"19","author":"Arcaini","year":"2008","journal-title":"Ann Oncol"},{"issue":"15s","key":"10.1016\/j.beha.2011.03.001_bib31","article-title":"Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy","volume":"28","author":"Pettengell","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2011.03.001_bib32","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","article-title":"Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2011.03.001_bib33","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2000.18.5.947","article-title":"Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies","volume":"18","author":"Micallef","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2011.03.001_bib34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.bmt.1704124","article-title":"Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma","volume":"32","author":"Howe","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.beha.2011.03.001_bib35","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/sj.bmt.1701781","article-title":"Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation","volume":"23","author":"Sobecks","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.beha.2011.03.001_bib36","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.1999.01627.x","article-title":"Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties","volume":"106","author":"Milligan","year":"1999","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1016\/j.beha.2011.03.001_bib37","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2004.06.016","article-title":"Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group","volume":"22","author":"Lenz","year":"2004","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2011.03.001_bib38","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","article-title":"Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study","volume":"21","author":"Montoto","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.beha.2011.03.001_bib39","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2011.03.001_bib40","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","article-title":"Treatment-related myelodysplasia and acute leukemia in non-Hodgkin\u2019s lymphoma patients","volume":"21","author":"Armitage","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2011.03.001_bib41","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1182\/blood.V95.5.1588.005k38_1588_1593","article-title":"Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors","volume":"95","author":"Krishnan","year":"2000","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2011.03.001_bib42","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1994.12.12.2527","article-title":"Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies","volume":"12","author":"Darrington","year":"1994","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2011.03.001_bib43","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/annonc\/mdf109","article-title":"Risk of therapy-related myelodysplastic syndrome\/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma","volume":"13","author":"Hosing","year":"2002","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.beha.2011.03.001_bib44","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1182\/blood-2002-04-1261","article-title":"Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study","volume":"101","author":"Metayer","year":"2003","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2011.03.001_bib45","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.bmt.1702631","article-title":"Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study","volume":"26","author":"Colombat","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.beha.2011.03.001_bib46","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood.V100.4.1141.h81602001141_1141_1152","article-title":"Intensive therapies in follicular non-Hodgkin lymphomas","volume":"100","author":"Hunault-Berger","year":"2002","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.beha.2011.03.001_bib47","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2011.03.001_bib48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/annonc\/mdl348","article-title":"Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas \u2013 results of a randomized comparison by the German Low-Grade Lymphoma Study Group","volume":"18","author":"Nickenig","year":"2007","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.beha.2011.03.001_bib49","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/bmt.2008.382","article-title":"Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma","volume":"43","author":"Hicks","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2011.03.001_bib50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbmt.2007.06.016","article-title":"Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and follicular international prognostic index","volume":"14","author":"Vose","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.beha.2011.03.001_bib51","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1080\/10428190701583983","article-title":"The pretransplant follicular lymphoma international prognostic index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation","volume":"48","author":"Keeney","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.beha.2011.03.001_bib52","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/sj.bmt.1705864","article-title":"The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma","volume":"40","author":"Pham","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.beha.2011.03.001_bib53","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.beha.2011.03.001_bib54","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.beha.2011.03.001_bib55","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.001_bib56","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.beha.2011.03.001_bib57","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2011.03.001_bib58","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin\u2019s lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2011.03.001_bib59","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2004-12-4690","article-title":"Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab","volume":"105","author":"Bennett","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2011.03.001_bib60","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1517\/14712598.5.4.577","article-title":"A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma","volume":"5","author":"Davies","year":"2005","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.beha.2011.03.001_bib61","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","article-title":"Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma","volume":"26","author":"Krishnan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2011.03.001_bib62","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2003-02-0622","article-title":"High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis","volume":"102","author":"Gopal","year":"2003","journal-title":"Blood"},{"issue":"15s","key":"10.1016\/j.beha.2011.03.001_bib63","article-title":"Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy","volume":"28","author":"Salles","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.001_bib64","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.405.405","article-title":"Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)","volume":"114","author":"Rummel","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2011.03.001_bib65","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00432-008-0453-8","article-title":"Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro","volume":"135","author":"Schmidt-Hieber","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.001_bib66","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2679.2679","article-title":"Peripheral blood stem cell mobilization after bendamustine containing chemotherapy in indolent lymphomas is possible. Results from the phase III study of B-R vs. CHOP-R (NHL 1\u20132003 trial) of the StiL (Study Group Indolent Lymphomas, Germany)","volume":"114","author":"Burchardt","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2011.03.001_bib67","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2002-09-2778","article-title":"Utility of FDG-PET scanning in lymphoma by WHO classification","volume":"101","author":"Elstrom","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2011.03.001_bib68","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/annonc\/mdl014","article-title":"18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading","volume":"17","author":"Wohrer","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2011.03.001_bib69","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-010-1539-5","article-title":"Diagnostic and prognostic impact of (18)F-FDG PET\/CT in follicular lymphoma","author":"Le Dortz","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.beha.2011.03.001_bib70","article-title":"FDG PET and [90Y]ibritumomab tiuxetan in patients with follicular lymphoma","author":"Lopci","year":"2010","journal-title":"Q J Nucl Med Mol Imaging"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T02:55:16Z","timestamp":1592535316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692611000284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1521692611000284"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2011.03.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}